Efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir+ Dasabuvir and Ribavirin in patients with compensated HCV cirrhosis
SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?